

Peer Brehm Christensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7848116/publications.pdf>

Version: 2024-02-01

63
papers

2,950
citations

393982

19
h-index

168136

53
g-index

66
all docs

66
docs citations

66
times ranked

4831
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176. | 3.7 | 1,619 |
| 2 | Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336. | 3.7 | 208 |
| 3 | Time Trend of the Prevalence of Hepatitis E Antibodies among Farmers and Blood Donors: A Potential Zoonosis in Denmark. <i>Clinical Infectious Diseases</i> , 2008, 47, 1026-1031. | 2.9 | 169 |
| 4 | Mortality in patients with chronic and cleared hepatitis C viral infection: A nationwide cohort study. <i>Journal of Hepatology</i> , 2010, 53, 36-42. | 1.8 | 82 |
| 5 | Dried blood spots, valid screening for viral hepatitis and human immunodeficiency virus in real-life. <i>World Journal of Gastroenterology</i> , 2016, 22, 7604. | 1.4 | 63 |
| 6 | Declining prevalence of hepatitis E antibodies among Danish blood donors. <i>Transfusion</i> , 2015, 55, 1662-1667. | 0.8 | 62 |
| 7 | Socioeconomic status in HCV infected patients & risk and prognosis. <i>Clinical Epidemiology</i> , 2013, 5, 163. | 1.5 | 59 |
| 8 | Hepatitis C prevalence in Denmark -an estimate based on multiple national registers. <i>BMC Infectious Diseases</i> , 2012, 12, 178. | 1.3 | 54 |
| 9 | High prevalence of hepatitis E antibodies among Danish prisoners and drug users. <i>Journal of Medical Virology</i> , 2002, 66, 49-55. | 2.5 | 45 |
| 10 | Outreach screening of drug users for cirrhosis with transient elastography. <i>Addiction</i> , 2011, 106, 970-976. | 1.7 | 41 |
| 11 | Microfibrillar-Associated Protein 4: A Potential Biomarker for Screening for Liver Fibrosis in a Mixed Patient Cohort. <i>PLoS ONE</i> , 2015, 10, e0140418. | 1.1 | 34 |
| 12 | Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. <i>Vaccine</i> , 2004, 22, 3897-3901. | 1.7 | 33 |
| 13 | Transfusion-acquired hepatitis C: the Danish lookback experience. <i>Transfusion</i> , 1999, 39, 188-193. | 0.8 | 32 |
| 14 | Transient elastography for liver fibrosis diagnosis. <i>European Journal of Internal Medicine</i> , 2009, 20, 339-342. | 1.0 | 30 |
| 15 | Liver Stiffness Measurement among Patients with Chronic Hepatitis B and C: Results from a 5-Year Prospective Study. <i>PLoS ONE</i> , 2014, 9, e111912. | 1.1 | 26 |
| 16 | Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. <i>Clinical Epidemiology</i> , 2017, Volume 9, 501-516. | 1.5 | 25 |
| 17 | Feasibility of transient elastography versus real-time two-dimensional shear wave elastography in difficult-to-scan patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1354-1359. | 0.6 | 23 |
| 18 | GB Virus C epidemiology in denmark: Different routes of transmission in children and low- and high-risk adults. <i>Journal of Medical Virology</i> , 2003, 70, 156-162. | 2.5 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: Results from the DANVIR cohort study. <i>International Journal of Cancer</i> , 2012, 130, 2310-2317. | 2.3 | 21 |
| 20 | Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study. <i>BMC Infectious Diseases</i> , 2011, 11, 177. | 1.3 | 20 |
| 21 | Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. <i>PLoS ONE</i> , 2020, 15, e0238203. | 1.1 | 20 |
| 22 | Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial. <i>Journal of Hepatology</i> , 2018, 68, 840-842. | 1.8 | 19 |
| 23 | PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 83-87. | 0.6 | 19 |
| 24 | Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 849-856. | 0.6 | 16 |
| 25 | Surveillance of HIV and Viral Hepatitis by Analysis of Samples from Drug Related Deaths. <i>European Journal of Epidemiology</i> , 2006, 21, 383-387. | 2.5 | 15 |
| 26 | Incidence, prevalence and risk factors for hepatitis C in Danish prisons. <i>PLoS ONE</i> , 2019, 14, e0220297. | 1.1 | 15 |
| 27 | Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C. <i>PLoS ONE</i> , 2019, 14, e0212036. | 1.1 | 15 |
| 28 | Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland—Using spontaneous resolvers as the benchmark comparator. <i>Hepatology</i> , 2016, 63, 1506-1516. | 3.6 | 13 |
| 29 | Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011. <i>Danish Medical Journal</i> , 2012, 59, C4465. | 0.5 | 13 |
| 30 | Postmortem Detection of Hepatitis B, C, and Human Immunodeficiency Virus Genomes in Blood Samples from Drug-Related Deaths in Denmark*. <i>Journal of Forensic Sciences</i> , 2009, 54, 1085-1088. | 0.9 | 12 |
| 31 | Nationwide Experience of Treatment with Protease Inhibitors in Chronic Hepatitis C Patients in Denmark: Identification of Viral Resistance Mutations. <i>PLoS ONE</i> , 2014, 9, e113034. | 1.1 | 11 |
| 32 | Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population—a Danish cohort study. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw527. | 1.9 | 11 |
| 33 | Liver biopsy performance and histological findings among patients with chronic viral hepatitis: A Danish database study. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 245-249. | 1.5 | 10 |
| 34 | Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx257. | 0.4 | 9 |
| 35 | Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. <i>Liver International</i> , 2021, 41, 2601-2610. | 1.9 | 9 |
| 36 | Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome. <i>PLoS ONE</i> , 2013, 8, e62674. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1177-1186. | 0.8 | 7 |
| 38 | Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome. <i>Journal of Viral Hepatitis</i> , 2021, 28, 302-316. | 1.0 | 7 |
| 39 | Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. <i>PLoS ONE</i> , 2020, 15, e0243725. | 1.1 | 7 |
| 40 | A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e93601. | 1.1 | 6 |
| 41 | Influence of Hepatitis C Virus and IL28B Genotypes on Liver Stiffness. <i>PLoS ONE</i> , 2014, 9, e115882. | 1.1 | 6 |
| 42 | Emergency department testing is feasible but ineffective to eliminate hepatitis C in Denmark. <i>Infectious Diseases</i> , 2021, 53, 930-941. | 1.4 | 5 |
| 43 | No transmission of blood-borne viruses among hospital staff despite frequent blood exposure. <i>Danish Medical Journal</i> , 2014, 61, A4907. | 0.5 | 5 |
| 44 | A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project. <i>BMC Infectious Diseases</i> , 2022, 22, 202. | 1.3 | 5 |
| 45 | Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1115-1119. | 0.6 | 3 |
| 46 | Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in Denmark. <i>Journal of Viral Hepatitis</i> , 2022, 29, 727-736. | 1.0 | 3 |
| 47 | Depressive symptoms are frequent among drug users, but not associated with hepatitis C infection. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 566-572. | 1.5 | 2 |
| 48 | Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment. <i>Microbiology Resource Announcements</i> , 2021, 10, e0075521. | 0.3 | 2 |
| 49 | Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2022, , . | 1.0 | 2 |
| 50 | Debilitating fatigue as a treatment indication in chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 63, 1533-1534. | 1.8 | 1 |
| 51 | Genetic Variants in the Apoptosis Gene BCL2L1 Improve Response to Interferon-Based Treatment of Hepatitis C Virus Genotype 3 Infection. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3213-3225. | 1.8 | 1 |
| 52 | Hepatitis A infection and vaccination among Danish blood donors. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 127-30. | 1.5 | 1 |
| 53 | Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin – A Randomized Controlled Clinical Trial. <i>Viruses</i> , 2022, 14, 614. | 1.5 | 1 |
| 54 | Hepatitis C prevalence in Denmark in 2016 – An updated estimate using multiple national registers. , 2020, 15, e0238203. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|----|-----------|
| 55 | Hepatitis C prevalence in Denmark in 2016â€”An updated estimate using multiple national registers. , 2020, 15, e0238203. | | 0 |
| 56 | Hepatitis C prevalence in Denmark in 2016â€”An updated estimate using multiple national registers. , 2020, 15, e0238203. | | 0 |
| 57 | Hepatitis C prevalence in Denmark in 2016â€”An updated estimate using multiple national registers. , 2020, 15, e0238203. | | 0 |
| 58 | Title is missing!. , 2020, 15, e0243725. | | 0 |
| 59 | Title is missing!. , 2020, 15, e0243725. | | 0 |
| 60 | Title is missing!. , 2020, 15, e0243725. | | 0 |
| 61 | Title is missing!. , 2020, 15, e0243725. | | 0 |
| 62 | Title is missing!. , 2020, 15, e0243725. | | 0 |
| 63 | Title is missing!. , 2020, 15, e0243725. | | 0 |